Medacta H1 2026 Revenue Grows 10% as Margins and Cash Flow Decline

Medacta reported revenue of EUR 368 million for the first half of 2026, a 9.7% growth rate in constant currency. While the orthopedic implant manufacturer maintained top-line expansion, it faced pressure on profitability and liquidity as gross margins contracted and free cash flow turned negative.

"H1 was probably our worst semester in the last five years after COVID. And we were comparing it with the best semester of Medacta history, which was probably H1 2025," said Francesco Siccardi, CEO of Medacta, in a statement regarding the results.

Margin Compression and Cash Flow Trends

The company's gross margin fell by 310 basis points to 65.2% during the period. This decline, combined with increased operational costs, resulted in a negative free cash flow of EUR 18.6 million for the semester. These figures differ from the performance the firm achieved in the same period last year.

Strategic Focus: Internal R&D vs. M&A

Management is reassessing its capital allocation strategy due to these financial results. Siccardi emphasized that the company is prioritizing internal development over external acquisitions to preserve returns on invested capital.

"Every time I look at price points paid for M&A, for technology, for products, the return on invested capital when we do it internally is incredibly better," said Siccardi.

Outlook and Expansion

Medacta is focusing on geographic diversification to support its market position. The company expects to begin shipments of its knee products to the Indian market in September 2026, following the receipt of necessary regulatory approvals.

These developments are relevant for stakeholders monitoring the company's ability to balance revenue targets with the operational discipline required to restore positive cash flow. The transition to negative cash flow indicates the current volatility in Medacta’s cost structure as it scales its product offerings globally.